Neurocrine Biosciences Inc. (NBIX), Thursday unveiled new data at the 2025 Psychiatry Update Conference in Chicago, highlighting the long-term efficacy of INGREZZA or valbenazine in treating tardive dyskinesia.
Tardive dyskinesia is a neurological disorder marked by involuntary, repetitive movements of the face, torso, or other body parts, which can be disruptive and adversely affect patients' quality of life.
Findings from the KINECT 4 study demonstrated that a majority of patients experienced remission after 48 weeks of once-daily treatment.
The post-hoc analysis, based on 103 participants, assessed remission using the Abnormal Involuntary Movement Scale. Results showed that 59.2 percent of patients met the remission threshold, with similar outcomes across both 40 mg and 80 mg doses.
A majority of participants achieved remission regardless of their psychiatric diagnosis or dosage level. Improvements were consistent across psychiatric conditions, reinforcing INGREZZA's effectiveness as a long-term treatment option.
NBIX is currently trading at $110.38, up $0.07 or 0.06 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.